Avalyn Pharma (NASDAQ:AVLN) Sets New 12-Month Low – Time to Sell?

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) reached a new 52-week low during mid-day trading on Thursday. The stock traded as low as $24.14 and last traded at $24.48, with a volume of 285265 shares changing hands. The stock had previously closed at $25.53.

Analysts Set New Price Targets

AVLN has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a report on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. Raymond James Financial initiated coverage on shares of Avalyn Pharma in a report on Friday, October 2nd. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Morgan Stanley lifted their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Avalyn Pharma Stock Down 3.4%

The stock has a market capitalization of $1.09 billion and a price-to-earnings ratio of -1.08. The stock has a 50-day simple moving average of $33.38. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.05. Equities analysts forecast that Avalyn Pharma Inc. will post -3.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp bought a new stake in shares of Avalyn Pharma during the second quarter valued at about $10,501,000. Braidwell LP purchased a new position in Avalyn Pharma during the second quarter valued at approximately $26,382,000. Montanova Capital LLC purchased a new position in Avalyn Pharma during the second quarter valued at approximately $82,402,000. Finally, Bank of New York Mellon Corp bought a new stake in Avalyn Pharma during the 2nd quarter worth approximately $1,321,000.

About Avalyn Pharma

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.